This article is more than 5 years old. Information may no longer be current.

Next phase of study of embryonic stem cell-derived RPE cells for dry AMD begins

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The next phase of a study of retinal pigment epithelial cells derived from human embryonic stem cells for the treatment of dry age-related macular degeneration has begun, according to a news release from Advanced Cell Technology.

The procedure, in which a patient was injected with 100,000 cells, took place Aug. 1 at Wills Eye Institute and was led by Carl D. Regillo, MD, FACS, OSN Retina/Vitreous Board Member, the release said. A similar procedure was performed by Regillo and his team in July to study human-derived stem cells for treatment of Stargardt’s macular dystrophy.

The prospective, open-label studies of dry AMD and Stargardt’s will each enroll 12 subjects, with cohorts of three subjects taking ascending dosages, the release said.

“We are encouraged by our ongoing progress in all three of our clinical trials using our hESC-derived RPE cells to treat forms of macular degeneration,” Gary Rabin, chairman and CEO of Advanced Cell Technology, said in the release. “We have not observed any complications or side effects from the stem cell-derived RPE cells, and we will continue to monitor the patients for safety, tolerability and efficacy of this therapy.”